(Image Credit - Franko Zeitz)
This morning, Nemus Bioscience (OTC:NMUS) announced that the company's topical CBD-analogue (NB2222) was able to penetrate multiple compartments of the eye, demonstrating significantly improved ocular absorption versus naturally derived CBD.
This pre-clinical research was conducted by the company's R&D partner, the University of Mississippi, and the results will be presented at the American Association of Pharmaceutical Scientists meeting in San Diego this November.
Going forward, Nemus and the University of Mississippi will be continuing to test various formulations of NB2222 and will be progressing to test the drug in animal models of ocular disease.
Dr. Soumyajit Majumdar, Professor of Pharmaceutics and Drug Delivery and Associate Dean for Research and Graduate Programs in the School of Pharmacy and lead scientist of the Nemus ophthalmic platform had this to say about the results:
"Topical NB2222 was able to penetrate multiple compartments of the eye including the retina-choroid and vitreous humor, tissues that help maintain optic nerve function. We did not see this type of ocular bioavailability with CBD derived from the plant and administered under identical testing conditions. We look forward to working with Nemus to advance this novel bio-engineered molecule into advanced formulation testing as well as studies examining specific animal models of ocular disease ahead of human studies."
Nemus' CEO and Chief Medical Officer, Brian Murphy, MD, MBA also expressed optimism regarding the company's ocular platform:
"The development of a comprehensive, multi-cannabinoid drug platform for ophthalmic uses is an important developmental goal for Nemus. Having access to both the prodrug of THC (NB1111) and the analogue of CBD (NB2222) could potentially add therapeutic indications to our proprietary ocular medicine platform, including dry eye syndrome, uveitis, and glaucoma in the anterior compartment of the eye, as well as macular degeneration and diabetic retinopathy in the posterior compartment."
In early trading Monday, shares of Nemus Bioscience are falling roughly 2% on light trading volume. We'll be watching to see how the markets continue to digest these optimistic results from early stage research.
Be sure to check out Nemus' marijuana stock profile to learn more and view a custom stock chart.
To stay up to date with developments in the cannabinoid biotech space be sure to subscribe to our free cannabinoid biotech & pharma email newsletter if you haven't already.
Don't be a stranger, connect with The Daily Marijuana Observer on Facebook, Twitter, StockTwits and Instagram!
Investing in nanocap, microcap, and small cap stocks is highly speculative. The publishers of DailyMarijuanaObserver.com are not registered as Investment Advisors or Broker-Dealers in any jurisdiction whatsoever. The information contained on DailyMarijuanaObserver.com (“this site”) has been prepared solely for informational purposes. Nothing on the site is an offer or solicitation to buy or sell securities. Investors should seek financial advice regarding the appropriateness of investing in any securities mentioned from their financial advisor.